Coherus BioSciences (CHRS) reported Q1 2025 financial results, highlighting its strategic transformation to innovative oncology. LOQTORZI generated net revenue of $7.3 million with >15% patient demand growth vs Q4 2024. The company completed the UDENYCA divestiture for up to $558.4 million, receiving $483.4 million upfront. Q1 results showed net loss from continuing operations of $47.4 million ($0.41/share). Key pipeline developments include positive Phase 1b data for CHS-114 in head and neck cancer and ongoing trials for casdozokitug combination therapy. Cash position was $82.4 million as of March 31, 2025. The company is advancing its oncology portfolio with LOQTORZI, the only FDA-approved treatment for nasopharyngeal carcinoma, while progressing clinical trials for CHS-114 and casdozokitug with data readouts expected in 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.